Organovo Holdings Inc ONVO shares are trading higher by 198.1% to $1.12 Tuesday morning after the company announced that Eli Lilly And Co LLY is set to acquire its FXR program, including FXR314.
What To Know: San Diego-based biotechnology company Organovo announced that Eli Lilly will acquire its FXR program, including lead asset FXR314, aimed at treating inflammatory bowel disease. Organovo Executive Chairman Keith Murphy called the deal a major milestone, highlighting Lilly’s expertise in drug development.
The agreement includes an upfront payment to Organovo, along with potential milestone payments tied to regulatory and commercial achievements. Lilly will gain full commercial and intellectual property rights to the FXR program for global development.
Read Also: Home Depot Lifts Annual Dividend After Strong Q4, But Soft 2025 Outlook Weighs On Stock
According to data from Benzinga Pro, ONVO has a 52-week high of $1.74 and a 52-week low of $0.32.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
